Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
28 hedge funds and large institutions have $6.71M invested in Amplify Treatments, Testing and Advancements ETF in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 13 reducing their positions, and 5 closing their positions.
7% less funds holding
Funds holding: 30 → 28 (-2)
27% less capital invested
Capital invested by funds: $9.18M → $6.71M (-$2.47M)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
85% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$769K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$688K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$371K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$53.5K |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
+$5.63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$769K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$486K |
| 3 |
Jane Street
New York
|
-$392K |
| 4 |
GBWM
Granite Bay Wealth Management
Portsmouth,
New Hampshire
|
-$314K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$214K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BHWM
26
Beaird Harris Wealth Management
Dallas,
Texas
| $1K | -$1.13K | -40 | -47% |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
RJFSA
28
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$769K | -21,572 | Closed |
|
|
29
Jane Street
New York
| – | -$392K | -10,992 | Closed |
|
|
WS
30
Wedbush Securities
Los Angeles,
California
| – | -$214K | -6,011 | Closed |
|
|
SCA
31
Snowden Capital Advisors
New York
| – | -$7K | -200 | Closed |
|
|
TWA
32
TCI Wealth Advisors
Tucson,
Arizona
| – | -$282 | -10 | -50% |
|
GERM Hedge Fund Activity: Q1 2022 in Review
28 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q1 2022, worth a combined $6.71M — down 27% from $9.18M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of GERM and 3 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 2 added.
The largest buyer was Goldman Sachs, adding an estimated $769K. The largest seller was Raymond James Financial Services Advisors, exiting entirely with an estimated $769K sold.
- 28 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q1 2022, down from 30 in Q4 2021.
- Funds reported $6.71M of Amplify Treatments, Testing and Advancements ETF stock for Q1 2022, down 27% quarter-over-quarter.
- 3 funds opened new Amplify Treatments, Testing and Advancements ETF positions in Q1 2022 and 5 closed out, a net change of -2 holders.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q1 2022 was Goldman Sachs, an estimated $769K added.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q1 2022 was Raymond James Financial Services Advisors, an estimated $769K sold.
Based on aggregated 13F filings for Q1 2022.